Activation of apoptosis signaling eliminates CD34 + progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors

Leukemia

Volumn 26, Issue 4, 2012, Pages 788-794

  Mak, D H ^a   Wang, R Y ^a   Schober, W D ^a   Konopleva, M ^a   Cortes, J ^a   Kantarjian, H ^a   Andreeff, M ^a   Carter, B Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

apoptosis; Bcl 2 Bcl xL; CML; Mcl 1; quiescent; XIAP

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BCR ABL PROTEIN; IMATINIB; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; TRIPTOLIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL;

ANTIGENS, CD34; APOPTOSIS; BIPHENYL COMPOUNDS; BLAST CRISIS; CELL LINE, TUMOR; DITERPENES; EPOXY COMPOUNDS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NITROPHENOLS; PHENANTHRENES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84859650054     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.285     Document Type: Article

References (27)

1. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res 1998; 22: 1085-1096. (Pubitemid 29002983)
2. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539. (Pubitemid 43801382)
3. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
4. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
5. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667. (Pubitemid 39063268)
6. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005; 19: 1034-1041. (Pubitemid 40862017)
7. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056-2064. (Pubitemid 29430422)
8. Amarante-Mendes GP, Naekyung KC, Liu L, Huang Y, Perkins CL, Green DR et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998; 91: 1700-1705. (Pubitemid 28110335)
9. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311.
10. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436-9444. (Pubitemid 41508012)
11. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388. (Pubitemid 44693472)
12. Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2007; 140: 181-190. (Pubitemid 350265045)
13. Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007; 14: 1667-1677. (Pubitemid 47278852)
14. Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 2003; 9: 4267-4273. (Pubitemid 37204048)
15. Carter BZ, Mak D, Schober WD, Cabreira-Hansen M, Beran M, McQueen T et al. Regulation of survivin expression through bcr-abl/MAPK cascade: targeting survivin overcomes Imatinib resistance and increases Imatinib sensitivity in Imatinib responsive CML cells. Blood 2006; 107: 1555-1563. (Pubitemid 43242394)
16. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009; 8: 2509-2516.
17. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
18. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993; 53: 3603-3610. (Pubitemid 23229644)
19. Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002; 62: 5995-5998. (Pubitemid 35244441)
20. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 2006; 5: 2223-2229. (Pubitemid 44546558)
21. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800. (Pubitemid 34534553)
22. Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, Uchiyama T et al. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 1989; 17: 145-153. (Pubitemid 19056039)
23. Issaad C, Croisille L, Katz A, Vainchenker W, Coulombel L. A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38-progenitor cells in long-term cultures and semisolid assays. Blood 1993; 81: 2916-2924. (Pubitemid 23162109)
24. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stroma cells prevent apoptosis of AML cells by upregulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713-1724.
25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
26. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108: 630-637. (Pubitemid 44061364)
27. Harousseau JLH, Dombret HD, Pigneux AP, Michallet MM, Brandely MB. Phase I study of F60008, a triptolide derivative, in patients with refractory or relapsing acute leukemias. 13th Congress of the European Hematology Association (EHA) 2008.